Table 3 Univariate and multivariate analyses of association of baseline prognostic factors with overall survival
From: Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
Univariate analyses | Multivariate analysis Patients with complete data ( N =247) | Multivariate analysis All patients, MI for missing values ( N =274) | ||||||
|---|---|---|---|---|---|---|---|---|
N | No. of deaths | Median survival, months (95% CI) | P -value | HR (95% CI) | P -value | HR (95% CI) | P -value | |
Age, years | ||||||||
<65 | 84 | 70 | 16.8 (14.2–19.5) | <0.001 | 1 (referent) | 0.019 | 1 (referent) | 0.022 |
⩾65 | 190 | 181 | 11.4 (10.4–13.3) | 1.45 (1.06–1.97) | 1.42 (1.05–1.91) | |||
Gender | ||||||||
Female | 37 | 34 | 15.7 (13.9–22.1) | 0.262 | 1 (referent) | 0.542 | 1 (referent) | 0.276 |
Male | 237 | 217 | 12.6 (11.2–14.5) | 1.13 (0.77–1.66) | 1.23 (0.85–1.80) | |||
Histology | ||||||||
Epithelioid | 115 | 104 | 15.9 (14.6–18.4) | <0.001 | 1 (referent) | 1 (referent) | ||
Sarcomatous | 32 | 31 | 7.8 (4.9–9.8) | 2.57 (1.62–4.07) | <0.001 | 2.56 (1.67–3.93) | <0.001 | |
Other | 127 | 116 | 12.6 (10.7–15.4) | 1.37 (1.02–1.83) | 0.035 | 1.39 (1.05–1.83) | 0.020 | |
AJCC stage | ||||||||
I–II | 137 | 120 | 14.8 (12.7–19.1) | 0.002 | 1 (referent) | 0.056 | 1 (referent) | 0.063 |
III–IV | 119 | 113 | 11.6 (9.5–14.5) | 1.31 (0.99–1.74) | 1.29 (0.99–1.69) | |||
Missing | 18 | 18 | ||||||
ECOG performance status | ||||||||
0–1 | 234 | 213 | 14.2 (13.1–16.5) | <0.001 | 1 (referent) | 0.008 | 1 (referent) | 0.005 |
2–3 | 32 | 30 | 6.1 (4.4–10.9) | 1.80 (1.17–2.77) | 1.78 (1.19–2.66) | |||
Missing | 8 | 8 | ||||||
Weight loss | ||||||||
Absent | 140 | 121 | 18.2 (14.2–21.2) | <0.001 | 1 (referent) | 0.002 | 1 (referent) | 0.001 |
Present | 125 | 121 | 11.0 (8.94–12.6) | 1.59 (1.18–2.14) | 1.61 (1.21–2.14) | |||
Missing | 9 | 9 | ||||||
Chest pain | ||||||||
Absent | 98 | 84 | 16.5 (13.3–20.2) | <0.001 | 1 (referent) | 0.048 | 1 (referent) | 0.045 |
Present | 169 | 160 | 12.0 (9.76–14.1) | 1.34 (1.00–1.79) | 1.32 (1.01–1.74) | |||
Missing | 7 | 7 | ||||||
Haemoglobin difference, g l −1 | ||||||||
<10 | 80 | 68 | 18.4 (15.2–24.2) | <0.001 | 1 (referent) | 0.090 | 1 (referent) | 0.095 |
⩾10 | 194 | 183 | 11.4 (10.4–13.3) | 1.33 (0.96–1.84) | 1.31 (0.95–1.79) | |||
White cell count (× 109 l−1) | ||||||||
⩽8.30 | 135 | 122 | 14.5 (12.6–17.8) | 0.109 | 1 (referent) | 0.745 | 1 (referent) | 0.765 |
>8.30 | 139 | 129 | 11.6 (10.4–14.0) | 1.05 (0.79–1.40) | 0.96 (0.73–1.26) | |||
Platelet count (× 109 l−1) | ||||||||
⩽400 | 197 | 176 | 15.2 (13.3–18.2) | <0.001 | 1 (referent) | 0.003 | 1 (referent) | <0.001 |
>400 | 77 | 75 | 9.6 (7.3–11.6) | 1.65 (1.19–2.28) | 1.71 (1.26–2.33) | |||
Neutrophil-to-lymphocyte ratio at baseline | ||||||||
<5 | 202 | 185 | 14.2 (12.7–16.3) | 0.122 | 1 (referent) | 0.835 | 1 (referent) | 0.939 |
⩾5 | 72 | 66 | 10.4 (8.1–13.1) | 1.03 (0.75–1.42) | 1.01 (0.75–1.36) | |||
